Compare · BMRA vs NTLA
BMRA vs NTLA
Side-by-side comparison of Biomerica Inc. (BMRA) and Intellia Therapeutics Inc. (NTLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and NTLA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NTLA is the larger of the two at $2.19B, about 395.8x BMRA ($5.5M).
- Over the past year, BMRA is down 41.6% and NTLA is up 70.5% - NTLA leads by 112.1 points.
- NTLA has been more active in the news (12 items in the past 4 weeks vs 2 for BMRA).
- NTLA has more recent analyst coverage (25 ratings vs 1 for BMRA).
- Company
- Biomerica Inc.
- Intellia Therapeutics Inc.
- Price
- $1.88-3.35%
- $15.66+2.96%
- Market cap
- $5.5M
- $2.19B
- 1M return
- -18.83%
- +31.27%
- 1Y return
- -41.59%
- +70.50%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 2
- 12
- Recent ratings
- 1
- 25
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest BMRA
- Biomerica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
- ConsumerDirect Expands Executive Team with Appointment of Gary Lu, CPA as Chief Financial Officer
- Citizens initiated coverage on Biomerica with a new price target
- Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
- Biomerica Reports Third Quarter Fiscal 2026 Financial Results
- SEC Form 10-Q filed by Biomerica Inc.
- Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
Latest NTLA
- Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Director Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)
- Director Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)
- Director Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)
- Director Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 units (SEC Form 4)
- Director Cohen Fred E was granted 9,200 shares, increasing direct ownership by 4% to 216,653 units (SEC Form 4)
- Director Chase William J was granted 9,200 shares, increasing direct ownership by 7% to 143,893 units (SEC Form 4)
- Director Bhanji Muna was granted 9,200 shares, increasing direct ownership by 34% to 36,403 units (SEC Form 4)
- Intellia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders